These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28880019)

  • 21. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy.
    Corey DR
    Nat Neurosci; 2017 Apr; 20(4):497-499. PubMed ID: 28192393
    [No Abstract]   [Full Text] [Related]  

  • 22. Evidence in focus: Nusinersen use in spinal muscular atrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Michelson D; Ciafaloni E; Ashwal S; Lewis E; Narayanaswami P; Oskoui M; Armstrong MJ
    Neurology; 2018 Nov; 91(20):923-933. PubMed ID: 30315070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic therapies for inherited neuromuscular disorders.
    Scoto M; Finkel R; Mercuri E; Muntoni F
    Lancet Child Adolesc Health; 2018 Aug; 2(8):600-609. PubMed ID: 30119719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.
    Dutta D; Chandra G; Mohanakumar KP
    J Neurochem; 2020 Jun; 153(5):545-548. PubMed ID: 32128827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Can you patent the sun?].
    Slørdal L
    Tidsskr Nor Laegeforen; 2018 Apr; 138(7):. PubMed ID: 29663751
    [No Abstract]   [Full Text] [Related]  

  • 26. Spinal muscular atrophy: A modifiable disease emerges.
    Fitzgerald DA; Abel F; Jones KJ; Farrar MA
    Paediatr Respir Rev; 2018 Sep; 28():1-2. PubMed ID: 30414816
    [No Abstract]   [Full Text] [Related]  

  • 27. Spinraza-a rare disease success story.
    Prakash V
    Gene Ther; 2017 Sep; 24(9):497. PubMed ID: 28963567
    [No Abstract]   [Full Text] [Related]  

  • 28. Nusinersen: First Global Approval.
    Hoy SM
    Drugs; 2017 Mar; 77(4):473-479. PubMed ID: 28229309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of serum sample preparation and chromatographic analysis of nusinersen used for the treatment of spinal muscular atrophy.
    Studzińska S; Szymarek J; Mazurkiewicz-Bełdzińska M
    Talanta; 2024 Jan; 267():125173. PubMed ID: 37690419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy.
    Biliouris K; Gaitonde P; Yin W; Norris DA; Wang Y; Henry S; Fey R; Nestorov I; Schmidt S; Rogge M; Lesko LJ; Trame MN
    CPT Pharmacometrics Syst Pharmacol; 2018 Sep; 7(9):581-592. PubMed ID: 30043511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.
    Luu KT; Norris DA; Gunawan R; Henry S; Geary R; Wang Y
    J Clin Pharmacol; 2017 Aug; 57(8):1031-1041. PubMed ID: 28369979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.
    Haché M; Swoboda KJ; Sethna N; Farrow-Gillespie A; Khandji A; Xia S; Bishop KM
    J Child Neurol; 2016 Jun; 31(7):899-906. PubMed ID: 26823478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Note: Zolgensma data manipulation.
    Med Lett Drugs Ther; 2019 Aug; 61(1579):129. PubMed ID: 31581156
    [No Abstract]   [Full Text] [Related]  

  • 34. Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: early results of technical success and safety.
    Weaver JJ; Natarajan N; Shaw DWW; Apkon SD; Koo KSH; Shivaram GM; Monroe EJ
    Pediatr Radiol; 2018 Mar; 48(3):392-397. PubMed ID: 29130140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultrasound-guided cervical puncture for nusinersen administration in adolescents.
    Ortiz CB; Kukreja KU; Lotze TE; Chau A
    Pediatr Radiol; 2019 Jan; 49(1):136-140. PubMed ID: 30167764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of the Method for Nusinersen and Its Metabolites Identification in the Serum Samples of Children Treated with Spinraza for Spinal Muscular Atrophy.
    Studzińska S; Mazurkiewicz-Bełdzińska M; Buszewski B
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nusinersen Use in Spinal Muscular Atrophy.
    Pediatrics; 2019 Jan; 143(1):. PubMed ID: 30584063
    [No Abstract]   [Full Text] [Related]  

  • 38. Reply to letter to the editor "Regarding nusinersen and other therapeutic strategies for improved motor function".
    Shimizu-Motohashi Y; Komaki H
    Brain Dev; 2023 Sep; 45(8):476-477. PubMed ID: 37321879
    [No Abstract]   [Full Text] [Related]  

  • 39. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How children and caregivers viewed the change from nusinersen to risdiplam for treating spinal muscular atrophy.
    Agosto C; Benedetti F; Salamon E; Mercante A; Papa S; Giacomelli L; Santini A; Benini F
    Acta Paediatr; 2023 Feb; 112(2):311-312. PubMed ID: 36222023
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.